Dr. Abdurahman Alghabban

Dr. Abdurahman Alghabban

Speaker
Day: Day 1
Time: 8:50am – 9:00am

Final Overall Survival Analysis Among Patients With FRα-Positive, Platinum-Resistant Ovarian Cancer (PROC)
Treated With Mirvetuximab Soravtansine (MIRV) vs Investigator’s Choice Chemotherapy (ICC) in the Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) Study

Scroll to Top